IGF2BP2 recognizes and combines with the m6A modification sites of PTTG3P to maintain its stability and expression, which results in YAP1 expression and ultimately promotes the malignant proliferation of CRC cells and CRC progression (42). Here, PTTG3P is linked to colorectal carcinoma.